Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera‐Mancilla, Carlos M. Villalón, Antoinette MaassenVanDenBrink
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 10, pp. 1237-1250
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials
Faraidoon Haghdoost, Francesca Puledda, David García‐Azorín, et al.
Cephalalgia (2023) Vol. 43, Iss. 4
Open Access | Times Cited: 75
The sense of stopping migraine prophylaxis
Linda Al‐Hassany, Hannah Lyons, Deirdre M. Boucherie, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 30
Prolactin and oxytocin: potential targets for migraine treatment
Anna K. Szewczyk, Samiye Ulutas, Tülin Aktürk, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 23
Navigating the Neurobiology of Migraine: From Pathways to Potential Therapies
Masaru Tanaka, Bernadett Tuka, László Vécsei
Cells (2024) Vol. 13, Iss. 13, pp. 1098-1098
Open Access | Times Cited: 13
Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders
Eduardo Rivera‐Mancilla, Usha M. Musterd‐Bhaggoe, Dennis J.L.G. Schutter, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 1
Dural Immune Cells, CGRP, and Migraine
Louis K. Balcziak, Andrew F. Russo
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 36
Gut microbiota and migraine
Joshua Crawford, Sufang Liu, Feng Tao
Neurobiology of Pain (2022) Vol. 11, pp. 100090-100090
Open Access | Times Cited: 34
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus
Eduardo Rivera‐Mancilla, Linda Al‐Hassany, Carlos M. Villalón, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 36
Epidemiology of clinically significant migraine in Israel: a retrospective database study
Alla Shifrin, Eytan Domany, Matanya Tirosh, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system
Nai Lee, Jihoon Ok, Yonghoon Kwon, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications
Simone de Vries Lentsch, Eloísa Rubio‐Beltrán, Antoinette MaassenVanDenBrink
Maturitas (2021) Vol. 145, pp. 73-77
Open Access | Times Cited: 23
Myocardial infarction associated with erenumab: A case report
Justine Perino, Virginie Corand, Elise Laurent, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2022) Vol. 42, Iss. 7, pp. 585-589
Open Access | Times Cited: 16
Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies
Zachary A. Sorrentino, Dimitri Laurent, Jairo Hernandez, et al.
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1120-1132
Closed Access | Times Cited: 13
A link between migraine and prolactin: the way forward
Parisa Gazerani
Future Science OA (2021) Vol. 7, Iss. 9
Open Access | Times Cited: 17
Migraine and Its Treatment from the Medicinal Chemistry Perspective
Ezgi Pehlivanlar, Simone Carradori, Rahime Şimşek
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 4, pp. 951-966
Open Access | Times Cited: 2
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication
Hans‐Christoph Diener, Arne May
Cephalalgia (2024) Vol. 44, Iss. 3
Open Access | Times Cited: 2
Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies
Davide Para, Chiara Camponovo, Gianna Carla Riccitelli, et al.
CNS Drugs (2024) Vol. 38, Iss. 10, pp. 819-825
Open Access | Times Cited: 2
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review
Abimael González‐Hernández, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2024)
Closed Access | Times Cited: 2
A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
Giuseppe Tringali, Catello Vollono, Paolo Calabresi, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 10
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies
Abimael González‐Hernández, Miguel Condés‐Lara, Enrique García-Boll, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 2, pp. 179-199
Closed Access | Times Cited: 9
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Lanfranco Pellesi, Roberto De Icco, Hassan Youssef Alawie, et al.
Expert Opinion on Drug Safety (2020) Vol. 20, Iss. 4, pp. 467-474
Open Access | Times Cited: 9
Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases
Vicente González‐Quintanilla, Sara Pérez‐Pereda, Andrea González‐Suárez, et al.
Cephalalgia (2021) Vol. 41, Iss. 11-12, pp. 1272-1275
Closed Access | Times Cited: 8
Zavegepant nasal spray for the acute treatment of migraine: A meta analysis
Muhammad Waqas, Faizan Ur Rehman Ansari, Anam Nazir, et al.
Medicine (2023) Vol. 102, Iss. 43, pp. e35632-e35632
Open Access | Times Cited: 3
Atogepant: an emerging treatment for migraine
Cecilia Rustichelli, Rossella Avallone, Anna Ferrari
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 6, pp. 653-662
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top